Earlier patient studies for accelerated development

Direct access to over 70 patient populations

As biopharmaceutical companies large and small strive to manage development cost, mitigate risk of Phase III failure, gather dose range data sooner, accelerate development timelines and obtain earlier efficacy signals, PAREXEL helps you meet these multiple goals in your early stage development. For many years, PAREXEL Early Phase has been busy establishing large global databases of patients for inclusion in Phase I patient studies and Proof of Concept trials. Our global network of clinical units now has access to over 70 diverse patient populations including treatment naive subjects.

PAREXEL Early Phase are right where you need us. We can provide all the services that you need for early phase studies in patients, but only those that you want. All of our programs are uniquely tailored to meet your need, providing flexibility for both large and small biopharma companies and perfectly aligning with your company's own expertise and resources.